1. Veeramani S, Blackwell SE, Thiel WH, Yang ZZ,
Ansell SM, Giangrande PH and Weiner GJ (2019) An RNA aptamer-based biomarker
platform demonstrates high soluble CD25 occupancy by IL2 in the serum of
follicular lymphoma patients. Cancer Immunol Res.7(9):1511-22. PMID: 31383650
2. Rogers LM,
Veeramani S, and Weiner GJ (2014) Complement in monoclonal antibody therapy of
cancer. Immunol Res. 59(1-3):203-10.
3. Zent CS, Taylor
RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ,
Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ,
Witzig TE. (2014) Chemoimmunotherapy for relapsed/refractory and progressive
17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab,
and low-dose rituximab is effective and tolerable and limits loss of CD20
expression by circulating CLL cells. Am J Hematol. 89(7):757-65.
4. Muniyan S, Chou
YW, Tsai TJ, Thomes P, Veeramani S, Benigno BB, Walker LD, McDonald JF, Khan
SA, Lin FF, Lele SM, Lin MF. (2014) p66Shc longevity protein regulates the
proliferation of human ovarian cancer cells. Mol Carcinog. doi: 10.1002/mc.22129.
[Epub ahead of print]
5. Veeramani S,
Chou YW, Lin FC, Muniyan S, Lin FF, Kumar S, Xie Y, Lele SM, Tu Y, Lin MF. (2012)
Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic
androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity
of prostate cancer cells. Free Radic Biol Med. 53(1):95-108.
6. Veeramani S,
Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner
GJ. (2011) Rituximab infusion induces NK activation in lymphoma patients with
the high affinity CD16 polymorphism. Blood. 118(12):3347-9.
7. Chuang TD, Chen
SJ, Lin FF, Veeramani S, Kumar S, Batra SK, Tu Y, Lin MF. (2010). Human
prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates
ErbB-2 and regulates prostate cancer cell growth. J Biol Chem. 285(31):23598-606
8. Wang SY,
Veeramani S, Racila E, Cagley J, Fritzinger D, Vogel CW, St John W, Weiner GJ. (2009)
Depletion of the C3 component of complement enhances the ability of
rituximab-coated target cells to activate human NK cells and improves the
efficacy of monoclonal antibody therapy in an in vivo model. Blood.
114(26):5322-30
9. Rajendran M,
Thomes P, Zhang L, Veeramani S, Lin MF. (2010) p66Shc--a longevity redox
protein in human prostate cancer progression and metastasis : p66Shc in cancer
progression and metastasis. Cancer Metastasis Rev. 29(1):207-222
10. Veeramani S,
Lee MS and Lin MF (2009) Histidine-dependent acid phosphatases – Novel
subfamily of protein tyrosine phosphatase Trends Biochem Sci 34(6):273-278
11. Alam SM,
Rajendran M, Ouyang S, Veeramani S, Li, Z and Lin MF (2008) A Novel Role of Shc
Adaptor Proteins in Steroid Hormone-Regulated Cancers. Endocr Relat Cancer. 16(1):1-16
12. Veeramani S,
Yuan TC, Lin FF, Lin MF (2008) Mitochondrial redox signaling by p66Shc is involved
in regulating androgenic growth stimulation of human prostate cancer cells.
Oncogene 27(37):5057-5068
13. Yuan TC, Lin
FF, Veeramani S, Chen SJ, Earp III HS, Lin MF (2007) ErbB-2 via PYK2 up-regulates
the adhesive ability of androgen receptor-positive human prostate cancer cells
Oncogene 26:7552-7559
14. Yuan TC,
Veeramani S and Lin MF (2007) Neuroendocrine-like prostate cancer cells: Neuroendocrine
transdifferentiation of prostate adenocarcinoma cells Endocr Relat Cancer,
14:531-547
15. Yuan TC,
Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK,
Lin MF (2006) Androgen deprivation induces human prostate epithelial neuroendocrine
differentiation of androgen-sensitive LNCaP cells Endocr Relat Cancer 13:
151-167
16. Veeramani S,
Igawa T, Yuan TC, Lin FF, Lee MS, Lin JS, Johansson SL and Lin MF (2005) Expression
of p66Shc protein correlates with proliferation of human prostate cancer cells
Oncogene 24: 7203-7212
17. Veeramani S,
Yuan TC, Chen SJ, Lin FF, Petersen JE, Shaheduzzaman S, Srivastava S,
MacDonald RG and Lin MF (2005) Cellular prostatic acid phosphatase: a protein tyrosine
phosphatase involved in androgen-independent proliferation of prostate
cancer Endocr Relat Cancer 12: 805-822